Estela Rodriguez, Associate Director of Community Outreach and Co-Lead Thoracic Site Disease Group of the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, shared a post on X:
“FDA Oncology approves taletrectinib (IBTROZI) for ROS1+ mNSCLC
High Response rates, high CNS activity (IC-ORR 76.5%)
TKI naive: ORR: 85-90% (TRUST-I – II) DOR ≥12 mo: 72%
TKI-pretreated: ORR: 52% -62% (TRUST-I-II) DOR ≥6 mo: 74%
low neuro side effects
TRAEs: liver tox, pneumonitis, QTc, hyperuricemia, myalgia.”
Title: Taletrectinib in ROS1+ Non–Small Cell Lung Cancer: TRUST
Authors: Maurice Pérol, Wei Li, Nathan A. Pennell, Geoffrey Liu, Yuichiro Ohe, Filippo De Braud, Misako Nagasaka, Enriqueta Felip, Anwen Xiong, Yongchang Zhang, Huijie Fan, Xicheng Wang, Shuanglian Li, Rose K. Lai, Feiwu Ran, Xianyu Zhang, Wenfeng Chen, Lyudmila Bazhenova, Caicun Zhou.
You can read the Full Article in the Journal of Clinical Oncology.
More posts featuring Estela Rodriguez.